Search
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawnRegdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.
Anisotropine methylbromide
go.drugbank.com/drugs/DB00517ApprovedAnisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. … Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant
Synonyms: Metilbromuro de octatropina, 8-Methyl-3-(2-propylpentanoyloxy)tropinium bromideMethylphenidate
go.drugbank.com/drugs/DB00422ApprovedInvestigationalIn contrast, low doses are found to selectively activate NE and DA neurotransmission within the prefrontal cortex which is an area of the brain thought to play a prominent role in ADHD pathophysiology, … When provided as Concerta®, methylphenidate is released through the patented Osmotic Controlled-Release Oral Delivery (OROS) system where 22% of the dose is provided as an immediate release and 78% is
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 3-RingSynonyms: methyl α-phenyl-α-(2-piperidyl)acetate, methyl α-phenyl-α-2-piperidinylacetateDaptomycin
go.drugbank.com/drugs/DB00080ApprovedInvestigational[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Categories: P-glycoprotein substratesProducts: CUBICIN® 350 MG POLVO PARA SOLUCIÓN INYECTABLE O INFUSIÓN, CUBICIN® 500 MG POLVO PARA SOLUCION INYECTABLE O INFUSIONPlerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigational[A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678] … [A7117] Compared to placebo with G-CSF, the plerixafor and G-CSF mobilization regimen has a higher probability of achieving the optimal CD34+ cell target for tandem transplantation in fewer apheresis procedures
Products: MOZOBIL®, Enjeksiyonluk Çözelti, 1 ADETOrphenadrine
go.drugbank.com/drugs/DB01173ApprovedInvestigationalA muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Mixtures: MYOGESIC-B, MYOGESIC-OCategories: Ethers, Chemically Close to Antihistamines, Cytochrome P-450 SubstratesNylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnNylidrin, also known as _buphenine_ belongs to the category of drugs called _vasodilators_, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. … Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment [L2279
Categories: 2-Amino-1-Phenylethanol Derivatives, Cytochrome P-450 SubstratesPlecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalPlecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). … It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Categories: Guanylate Cyclase-C Agonist, Guanylyl Cyclase C AgonistsRetifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigationalBy blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. … Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsSynonyms: Anti-PD-1 monoclonal antibody MGA012Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalRecently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK … It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors